Investorideas.com - Cannabis Stock News: Village Farms International (TSX: $VFF.TO) (NASDAQ: $VFF) Ranks Number Three of 30 Top-Performing Companies in Inaugural TSX30 Program
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Thursday, 26 September 2019
Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move: Safe Banking Act Passed- News from (CSE: $HARV.C) (TSX: $VFF.TO) (NASDAQ: $VFF) (TSX.V: $PURE.V) (NYSE: $CGC)
Investor Ideas #Potcasts; #Cannabis News and #Stocks on the Move: Safe
Banking Act Passed- News from (CSE: $HARV.C) (TSX: $VFF.TO) (NASDAQ: $VFF)
(TSX.V: $PURE.V)
(NYSE: $CGC)
Delta, Kelowna, BC –September 26 , 2019
(Investorideas.com Newswire) www.Investorideas.com, a global news source
covering leading sectors including marijuana and hemp stocks and its potcast
site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM -
cannabis news and stocks to watch plus insight from thought leaders and
experts.
Listen to the podcast:
Read this in full
at https://www.investorideas.com/news/2019/cannabis-potcasts/09261HARV-VFF-PURE-CGC.asp
Good afternoon and welcome to another episode of
Investorideas.com "Potcast" featuring cannabis news, stocks to watch
as well as insights from thought leaders and experts
In
today’s podcast we look at a few early announcements.
But
first, yesterday the U.S. House of Representatives voted in favor of the Secure and Fair Enforcement (SAFE)
Banking Act, a landmark bill that would provide safe harbor and guidance to
financial institutions that work with legal cannabis businesses. The historic
vote was the first time that a standalone marijuana bill has come before the
full House. The vote needed a two-thirds majority to pass and was supported by
321 votes in favor to 103 against.
For years, cannabis businesses have been
hamstrung by their inability to access bank financing for acquisitions,
operations and expansion. It has also forced the industry to operate largely in
cash.
While the Democratic-controlled House of
Representatives voted to pass the bill protecting banks that work with the
marijuana industry, some analysts are still warning that the measure isn’t
likely to become law in 2019 as it faces a tough road in the
Republican-controlled Senate.
The chances of enactment this year for the
bill — known as the Secure And Fair Enforcement (SAFE) Banking Act — have risen
to 1 in 3, up from 1 in 5, reckons Ian Katz, an analyst at Capital Alpha
Partners. Those still aren’t great odds, however. “We remain skeptical for
now,” Katz said in a note before the House vote, though he added that the
chances could get better “if we see meaningful signals from the Senate in the
next few weeks.”
Many in the industry are also looking at
the MORE Act as the next legislation to hopefully pass through the house. The
Marijuana
Opportunity Reinvestment and Expungement (MORE) Act would remove cannabis from the Controlled
Substances Act and take steps to begin repairing the harms of the war on drugs.
The bill is sponsored by House Judiciary Committee Chairman, Jerrold Nadler
(D-NY), who has already signaled that he is committed to advancing it through
the House.
Also, StrainprintR Technologies Ltd., the leader in cannabis data and
analytics, announced the release of
The Canadian Medical Cannabis Experience: A 2019 Patient Retrospective, the latest Strainprint research
publication designed to support the entire cannabis industry with meaningful
insights based on the technology leader's unique and broad-based patient-led
data. The Report features thorough analysis of more than 800,000 real-time
anonymous patient outcomes reported during the period from January to December
2018.
"We
hear time and time again about the need for comprehensive resources like our
Patient Retrospective Report," said Strainprint President, Dave Berg.
"Medical cannabis hasn't had decades of clinical trials to form guidelines
on dosing, onset and efficiency and with over 450 chemical constituents in
every strain, it is not like studying single molecules in traditional
pharma. So, real-world patient data is
invaluable for medical professionals and industry stakeholders looking to make
informed choices for their patients and businesses."
Strainprint
aggregates anonymous patient-reported data from its
award-winning mobile journaling App and through surveys and validated
questionnaires from its online Strainprint Community. Strainprint has been
collecting this unique and proprietary data since 2016 and it grows more
granular by the day. Today, it is the largest data set of its kind in the world
with more than 1.4 million sessions and 70 million data points on strain
efficacy. It is the only cannabis consumption data tracked in real time against
more than 1,600 lab-verified products by batch.
"Tracking
symptomatic improvement against chemical profile (ingredients) by batch is the
only way for the industry to advance the scientific understanding of
cannabis," said Michelle Arbus, Strainprint VP of Research. "We are
fortunate in Canada to have a federal program with very high lab testing
requirements, consistent across the country, giving us the most standardardized
products from which to study and the best chance at personalizing cannabis as a
medicine."
The
2019 Patient Retrospective Report is the cutting edge of cannabis research and
a major milestone for the cannabis industry. The Report analyzes user variables
such as age, gender, region, usage frequency and efficacy by symptom and is the
first research set able to identify which terpenes are active in the cannabis
products that are reported to have the highest efficacy by symptom. A few key
findings from the Report include:
● Muscle pain, anxiety, depression, joint
pain and insomnia are the top five symptoms that patients treated with cannabis
during the Report period;
● There are clear gender differences for the
preferred choice of cannabis administration and the most effective methods of
can vary by region, gender and age;
● Multiple cannabis species are reported to
offer comparable relief for particular symptoms, supporting the hypothesis that
it is more than the species or the THC:CBD content that determines efficacy of
a strain;
● Patients overwhelmingly report positive and
or neutral emotive effects from their medical cannabis use with very few
unfavorable side effects. As well, the
specific terpene profiles present in a strain can greatly impact the side
effects; and
● There was no significant change in how or
when patients treated their various symptoms after cannabis was legalized
recreationally in Canada.
●
While
more study is certainly needed, Strainprint has raised the bar for cannabis
industry research with the largest and most granular real-world observational
patient study available. Strainprint Reports complement this data with
actionable insights and are available for purchase at
https://strainprint.ca/strainprint-reports/.
As
well, Investorideas recently interviewed Andrew Muroff the CEO of Strainrpint
at the ICBC Conference in Vancouver, regarding the company's recent reports. To
listen click here.
Harvest Health
& Recreation, Inc. (CSE: HARV) (OTCQX: HRVSF) today announced an exclusive partnership with Last
Prisoner Project ("LPP"), a new non-profit organization committed to
making sure that every cannabis prisoner is released, welcomed home and
supported by their community. Harvest is the first large cannabis company to
create a proprietary program focused on job creation for formerly incarcerated
prisoners that have been affected by the criminalization of cannabis. Harvest
and LPP's "Prison to Prosperity" pipeline of talent will focus on
facilitating re-entry of individuals impacted by the war on drugs back into
society, through workshop training programs, with the goal of providing
employment opportunities at Harvest locations nationwide.
According
to the US Department of Justice Bureau of Justice Statistics, within three
years of release over two-thirds of released prisoners are re-arrested, and
within six years of release that number jumps to 79%. The "Prison to
Prosperity" program is designed to reverse this statistic and demonstrates
Harvest's continued commitment to social justice, diversity and inclusion. It
is designed to bring restorative justice to communities most affected, while
bringing positive economic impacts to the residents and communities that the
company serves.
"Over
40,000 prisoners in the U.S. are currently serving sentences for cannabis
charges. While many companies are
focused on decriminalization, expungement and clemency, Harvest recognized that
re-entry can be incredibly difficult without help," said Harvest Chief
Executive Officer Steve White. "We've partnered with the Last Prisoner
Project to provide training courses, workshops and funding to help individuals
re-enter the job marketplace, with the hope of ultimately placing them in
employment opportunities within our Harvest network."
"I
launched the Last Prisoner Project out of the conviction that it is wrong to
continue to punish people for something society has decided should no longer be
illegal, and in the belief that if I asked the legal cannabis industry to
contribute the funds needed to gain the release of our prisoners, cannabis
companies would see it as an opportunity to do the right thing, to put the
values cannabis teaches into action," said Steve DeAngelo, Founder of Last
Prisoner Project. "I am pleased and heartened by the response so far from
cannabis companies and by many world-renowned musicians, including Stephen and
Damian Marley, Willie Nelson, and Eric Rachmany. This overwhelmingly positive
response gives me high hopes and strong confidence that the day will come when
the last cannabis prisoner on Planet Earth is free to come home to their
families. Until then, our mission continues."
Harvest's
"Prison to Prosperity" program will offer vocational training
opportunities and educational programs specific to the cannabis industry for
those who continue to be disadvantaged by a criminal record. The program will
begin with a pilot project working in tandem with local reentry organizations
in California and will roll out nationally at a later date.
Pure Global
Cannabis Inc. (TSX.V: PURE) (OTC: PRCNF) announced the creation of a new business unit,
PureCanna Solutions. This B2B brand will provide white label extraction,
co-processing, co-manufacturing, tolling, and cannabis and CBD isolate and
extract bulk sales.
PureCanna
has already entered into negotiations with potential clients and suppliers to
provide immediate access to the Company's extensive line of products and
manufacturing techniques, which include packaging for dried flower, oils
bottles, vape pens, and capsules. As the Company continues to upscale their
manufacturing and processing capabilities, the creation of this new division
will offer significant revenue generating potential with exceptional margins.
Pure
Global CEO & President, Malay Panchal said, "This new division will
allow us to quickly and substantially increase high margin sales by servicing
industry partners who share the same vision of creating only the highest
quality products. Adding CBD bulk sales, white label, and co-processing
services leverages our existing capabilities and any underutilized
capacity."
In
preparation for this development, the Company submitted their readiness
packages in early August for Health Canada approvals of Phase 2 of their
Brampton facility expansion, which upon approvals will immediately allow for
cultivation along with manufacturing capabilities of 20 to 30kg of cannabis
extract for bulk sale via CO2 supercritical extraction. PureSinse is in the
process of adding significantly more extraction capacity for hemp biomass
processing in place of previously denominated cultivation rooms with target
capacities of 100 to 200 tons annually and expected readiness in early H1 2020.
This
represents the latest in a series of transformational announcements from Pure
Global. The Company announced earlier this week the signing of a joint
operating agreement with KMT-Hansa Corp. to cultivate, grow and process hemp
and CBD products in China. In addition, Pure was recently granted their oil
sales license from Health Canada.
Mr.
Panchal continued, "PureCanna is set to become a leading provider of GMP
and pharmaceutical grade CBD and cannabinoid isolates, ready to use
formulations, co-manufacturing, and co-packaging services for CPG companies and
LPs. I am very proud of the hard work that has gone into the development of
this unit and look forward to forging new partnerships with some highly
respected cannabis and CPG companies in Canada and globally."
Village Farms
International, Inc. (TSX: VFF) (NASDAQ: VFF) today announced that it has ranked as the third
top-performing company in Toronto Stock Exchange's (TSX) inaugural TSX30, a
flagship program recognizing the 30 top-performing TSX stocks over a three-year
period based on dividend-adjusted share price appreciation.
"Since
Village Farms first publicly listed its shares in 2006, Toronto Stock Exchange
has been an outstanding platform for investors to participate in the growth of
our Company to one of the largest vertically integrated greenhouse growing
operations in North America," said Michael DeGiglio, CEO and Founder,
Village Farms International. "Now, leveraging more than three decades as a
leader in large-scale, precision agriculture, we are adding to our legacy
produce business with the biggest opportunity in our history as we pursue
outsized, long-term growth potential in the cannabis and CBD markets."
"Although
this award recognizes outstanding recent performance, Village Farms is only
just beginning to realize the value of these significant new growth
opportunities, which have transformed both our near- and long-term earnings
potential, and which we expect will drive growth for years to come. Our financial results are just starting to
benefit from the success of our 50%-owned joint venture for large-scale,
low-cost, high-quality cannabis production in Canada, Pure Sunfarms, which is
already one of the most profitable companies in the industry. Moreover, financial performance in the coming
quarters should reflect Pure Sunfarms recent ramp to full capacity at its first
greenhouse, the planned doubling of capacity next year with the conversion of a
second greenhouse, and the potential to more than double that capacity again
through the option to add a third greenhouse."
"In
parallel, in the United States we are aggressively pursuing the significant
opportunity in hemp and CBD. We expect
to generate our first hemp biomass sales later this year, and then rapidly
transition into higher margin CBD crude oil and then our own CBD products, as
we build a leading consumer packaged goods company in this exciting,
high-growth market. All of this should drive even further value for our
shareholders over both the short and long terms."
"We
are extremely proud to present the TSX30, a new recognition program featuring
some of the most compelling success stories among our listed issuers, including
companies operating in traditional areas of strength like natural resources and
also in newly defined sectors like clean tech and cannabis," said Loui
Anastasopoulos, President, Capital Formation, TMX Group. "TSX listed
companies play a vital role in Canada's capital markets and as we continue to
evolve into a global leader, TSX remains committed to our work in support of
this crucial ecosystem. Today, we congratulate the companies included in the
inaugural TSX30 for all of their achievements and look forward to continuing to
serve them along each stage of their growth path into the future."
Spectrum
Therapeutics, the
medical division of Canopy Growth
Corporation (TSX: WEED) (NYSE: CGC) announced a donation to the Fondation de l'Hôpital
du Sacré-Coeur de Montreal (Montreal Sacre Coeur Hospital Foundation) to
support the Canadian Sleep and Circadian Network's ("CSCN")
associated national campaign: Sleep On It which aims to raise awareness about
the importance of good quality sleep on health.
Spectrum's donation to the campaign has
been made, based on CSCN's request to support their initiative to organize the
sleep scientific community around the question of cannabis use for sleep
disorders. Although an increasing volume of anecdotal data indicates the
growing usage of cannabis from individuals coping with sleep disorders,
clinical scientific evidence on its effectiveness is still limited. Hence, via
this donation, CSCN will be able to provide to the public, health management
decision makers as well as the sleep scientific community, a review of
currently available data and identify the research gaps that need to be filled.
This review is expected to be completed during the second half of the 2020
calendar year.
By partnering with the leader in the
cannabis industry, CSCN's objective is to combine the expertise of clinicians,
physicians and researchers across the country to facilitate and scientifically
support the development of a white paper based on a comprehensive review of all
existing literature and facts about the use of cannabis in sleep disorder
management. The report is also expected to be published during the second half
of the 2020 calendar year and will introduce an updated clinical research
program looking at all areas that impact quality of sleep, including pain,
aging, and sleep disorders such as insomnia. Ultimately, the white paper will
provide insights and guidance on future research directions and further
requirements for evidence on the potential application of medical cannabis in
treating sleep disorders.
"Good quality sleep is far more
important to our long-term health than most people realize," commented Dr.
Mark Ware, Chief Medical Officer, Canopy Growth. "We're just now beginning
to explore the role cannabis can play in addressing sleep-related disorders.
Patient feedback is very promising so far, and partnerships such as these will
advance our understanding of the intriguing phenomenon of sleep that is so
essential to our overall well-being."
"The legalization of cannabis in
Canada has brought about a natural interest in the potential for cannabis in
the treatment of sleeping disorders. We need to catalyze the development of
collective efforts to further develop scientific knowledge platforms to inform
policy, therapeutic practice, and prevention efforts about sleep and cannabis
and to scientifically inform decision makers as well as the general public
about the research needs to produce evidence based data on sleep and
cannabis," commented Dr Julie Carrier, Scientific Director of the Canadian
Sleep & Circadian Network and sleep researcher at the CIUSSS du
Nord-de-l'Île-de-Montreal.
One
in three Canadians don't get the recommended seven hours of sleep each night.
The CSCN's mission is to mobilize the healthcare community to adopt an
integrated approach towards improving outcomes and treatment of patients with
sleep disorders.
Investor ideas reminds all listeners to read our disclaimers and
disclosures on the
Investorideas.com website and this podcast is not an endorsement to
buy products or services or securities. Investors are reminded all investment
involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also
available on iTunes, Spotify, Google
Play Music, Stitcher, Spreaker, YouTube
via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark
on the blockchain through Cognate, Inc. CM Certification-Registration Number:
10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news
source publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto,
technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily Crypto Corner and Podcast, Play
by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News
and Stocks on the Move podcast and column,
Cleantech and Climate Change Podcast and
the AI
Eye Podcast and column covering developments in
AI.
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions. More disclaimer info:
https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where
permissible by law. Our site does not possess, distribute, or sell cannabis
products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
Wednesday, 25 September 2019
Investorideas.com - Cannabis Stock News: Diego Pellicer Worldwide, Inc. (OTCQB: DPWW) Executes Letter Of Intent To Purchase A Second Cannabis Cultivation Facility In Denver
Investorideas.com - Cannabis Stock News: Diego Pellicer Worldwide, Inc. (OTCQB: DPWW) Executes Letter Of Intent To Purchase A Second Cannabis Cultivation Facility In Denver
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Investorideas.com - Cannabis Stock News: Tree of Knowledge (CSE: TOKI) (OTCBB: TOKIF) and Ryerson University's Nanotechnology Research Project Expands to Include the Development of Targeted Treatments for Cancer Tumours
Investorideas.com - Cannabis Stock News: Tree of Knowledge (CSE: TOKI) (OTCBB: TOKIF) and Ryerson University's Nanotechnology Research Project Expands to Include the Development of Targeted Treatments for Cancer Tumours
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Investorideas.com - SinglePoint's (OTCQB: SING) Pure Hemp Cigarette NACS Marketing Strategy Shows Strong Early Success
Investorideas.com - SinglePoint's (OTCQB: SING) Pure Hemp Cigarette NACS Marketing Strategy Shows Strong Early Success
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Get the latest Cannabis and Hemp stock news from www.investorideas.com
Subscribe to:
Posts (Atom)
-
New #Cannabis Stocks Added to Investor Ideas; (TSX: $FAF.V) (CSE: $STIL.C) (CSE: $ORCD.C) (CSE: $VREO.C) (CSE: $PUMP.C) (OTC: $NUGL) ... -
Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: Dixie Brands (CSE: $DIXI_U.C) (OTC: $DXBRF), Khiron Life Sciences (T... -
Investorideas.com - CBD Stock News: InnoCan Pharma (CSE: INNO) Announces the Successful Completion of an Independent Clinical Study Demonstr...